- Home
- TEN vs AUTL Comparison
TEN vs AUTL Comparison
Compare TEN & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- AUTL
- Stock Information
- Founded
- TEN 1993
- AUTL 2014
- Country
- TEN Greece
- AUTL United Kingdom
- Employees
- TEN N/A
- AUTL N/A
- Industry
- TEN
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TEN
- AUTL Health Care
- Exchange
- TEN NYSE
- AUTL Nasdaq
- Market Cap
- TEN 531.7M
- AUTL 609.4M
- IPO Year
- TEN N/A
- AUTL 2018
- Fundamental
- Price
- TEN $18.71
- AUTL $2.22
- Analyst Decision
- TEN Buy
- AUTL Strong Buy
- Analyst Count
- TEN 2
- AUTL 3
- Target Price
- TEN $31.00
- AUTL $10.20
- AVG Volume (30 Days)
- TEN 357.0K
- AUTL 1.4M
- Earning Date
- TEN 02-15-2025
- AUTL 03-13-2025
- Dividend Yield
- TEN 9.63%
- AUTL N/A
- EPS Growth
- TEN N/A
- AUTL N/A
- EPS
- TEN 5.46
- AUTL N/A
- Revenue
- TEN $836,042,000.00
- AUTL $10,091,000.00
- Revenue This Year
- TEN N/A
- AUTL $851.83
- Revenue Next Year
- TEN $7.39
- AUTL $264.18
- P/E Ratio
- TEN $3.42
- AUTL N/A
- Revenue Growth
- TEN N/A
- AUTL 82.71
- 52 Week Low
- TEN $15.88
- AUTL $2.07
- 52 Week High
- TEN $31.48
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- TEN 51.27
- AUTL 38.18
- Support Level
- TEN $17.50
- AUTL $2.18
- Resistance Level
- TEN $20.59
- AUTL $2.38
- Average True Range (ATR)
- TEN 0.70
- AUTL 0.16
- MACD
- TEN 0.30
- AUTL 0.01
- Stochastic Oscillator
- TEN 54.25
- AUTL 7.94
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.